slno-10q_20220630.htm
false Q2 SOLENO THERAPEUTICS INC 0001484565 --12-31 P5Y P1Y6M P2Y 0.00 0.00 0.00 0.00 P5Y6M P5Y6M P5Y6M P5Y6M P6Y P6Y P6Y P6Y 0.009 0.017 0.006 0.010 0.030 0.010 0.90 0.91 0.88 0.91 0.93 1.02 0.93 1.08 P7Y11M8D P7Y11M8D P6Y8M26D P7Y11M4D 0001484565 2022-01-01 2022-06-30 xbrli:shares 0001484565 2022-08-04 iso4217:USD 0001484565 2022-06-30 0001484565 2021-12-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2022-06-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2021-12-31 iso4217:USD xbrli:shares 0001484565 2022-04-01 2022-06-30 0001484565 2021-04-01 2021-06-30 0001484565 2021-01-01 2021-06-30 0001484565 us-gaap:CommonStockMember 2021-12-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001484565 us-gaap:RetainedEarningsMember 2021-12-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001484565 2022-01-01 2022-03-31 0001484565 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001484565 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001484565 us-gaap:CommonStockMember 2022-03-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001484565 us-gaap:RetainedEarningsMember 2022-03-31 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001484565 2022-03-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001484565 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001484565 us-gaap:CommonStockMember 2022-06-30 0001484565 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001484565 us-gaap:RetainedEarningsMember 2022-06-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001484565 us-gaap:CommonStockMember 2020-12-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001484565 us-gaap:RetainedEarningsMember 2020-12-31 0001484565 2020-12-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001484565 2021-01-01 2021-03-31 0001484565 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001484565 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001484565 us-gaap:CommonStockMember 2021-03-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001484565 us-gaap:RetainedEarningsMember 2021-03-31 0001484565 2021-03-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001484565 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001484565 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001484565 us-gaap:CommonStockMember 2021-06-30 0001484565 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001484565 us-gaap:RetainedEarningsMember 2021-06-30 0001484565 2021-06-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2022-01-01 2022-06-30 0001484565 slno:UnderwrittenPublicOfferingMember 2022-03-01 2022-03-31 0001484565 slno:UnderwrittenPublicOfferingMember 2022-03-31 0001484565 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2022-06-30 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2022-06-30 0001484565 slno:EssentialisIncMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001484565 us-gaap:FairValueInputsLevel3Member slno:EssentialisIncMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001484565 us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001484565 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2021-12-31 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2021-12-31 0001484565 slno:EssentialisIncMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001484565 us-gaap:FairValueInputsLevel3Member slno:EssentialisIncMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001484565 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001484565 slno:EssentialisIncMember 2017-03-07 0001484565 slno:EssentialisIncMember 2021-12-31 xbrli:pure 0001484565 2021-01-01 2021-12-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2021-12-31 0001484565 slno:PurchasePriceContingentLiabilityMember 2021-12-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2022-01-01 2022-06-30 0001484565 slno:PurchasePriceContingentLiabilityMember 2022-01-01 2022-06-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2022-06-30 0001484565 slno:PurchasePriceContingentLiabilityMember 2022-06-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2020-12-31 0001484565 slno:PurchasePriceContingentLiabilityMember 2020-12-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2021-01-01 2021-06-30 0001484565 slno:PurchasePriceContingentLiabilityMember 2021-01-01 2021-06-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2021-06-30 0001484565 slno:PurchasePriceContingentLiabilityMember 2021-06-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2018-12-19 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember srt:MinimumMember 2022-06-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2022-04-01 2022-06-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2021-04-01 2021-06-30 0001484565 us-gaap:MeasurementInputPriceVolatilityMember slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember 2022-06-30 0001484565 us-gaap:MeasurementInputPriceVolatilityMember slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember 2021-12-31 0001484565 us-gaap:MeasurementInputExpectedTermMember slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember 2022-06-30 0001484565 us-gaap:MeasurementInputExpectedTermMember slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember 2021-12-31 0001484565 us-gaap:MeasurementInputRiskFreeInterestRateMember slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember 2022-06-30 0001484565 us-gaap:MeasurementInputRiskFreeInterestRateMember slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember 2021-12-31 0001484565 us-gaap:MeasurementInputExpectedDividendRateMember 2022-06-30 utr:sqft 0001484565 stpr:CA 2021-04-30 0001484565 stpr:CA 2022-01-01 2022-06-30 0001484565 stpr:CA 2021-04-01 2021-04-30 0001484565 stpr:CA 2019-07-01 2019-07-31 0001484565 slno:FacilityLeasesMember 2022-06-30 0001484565 slno:FacilityLeasesMember 2021-12-31 0001484565 slno:CantorFitzgeraldAndCoMember slno:ControlledEquityOfferingSalesAgreementMember 2021-07-31 0001484565 slno:CantorFitzgeraldAndCoMember slno:ControlledEquityOfferingSalesAgreementMember 2022-01-01 2022-06-30 0001484565 slno:WarrantsToPurchaseCommonStockMember slno:TwoThousandAndTenAndTwoThousandAndTwelveConvertiblePromissoryNotesMember 2022-06-30 0001484565 slno:WarrantsToPurchaseCommonStockMember slno:TwoThousandAndTenAndTwoThousandAndTwelveConvertiblePromissoryNotesMember 2022-01-01 2022-06-30 0001484565 slno:UnderwriterMember 2022-06-30 0001484565 slno:UnderwriterMember 2022-01-01 2022-06-30 0001484565 srt:MinimumMember 2022-06-30 0001484565 us-gaap:EmployeeStockOptionMember srt:MinimumMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2022-01-01 2022-06-30 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2022-01-01 2022-06-30 0001484565 slno:IncentiveStockOptionsMember srt:MaximumMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2022-01-01 2022-06-30 0001484565 us-gaap:EmployeeStockOptionMember srt:MaximumMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2022-01-01 2022-06-30 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2022-06-30 0001484565 slno:TwoThousandTwentyInducementEquityIncentivePlanMember 2022-06-30 0001484565 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001484565 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001484565 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001484565 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001484565 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001484565 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001484565 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001484565 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001484565 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001484565 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001484565 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001484565 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001484565 us-gaap:PerformanceSharesMember 2021-04-01 2021-06-30 0001484565 us-gaap:PerformanceSharesMember 2021-01-01 2021-06-30 0001484565 srt:MinimumMember 2022-04-01 2022-06-30 0001484565 srt:MinimumMember 2021-04-01 2021-06-30 0001484565 srt:MinimumMember 2022-01-01 2022-06-30 0001484565 srt:MinimumMember 2021-01-01 2021-06-30 0001484565 srt:MaximumMember 2022-04-01 2022-06-30 0001484565 srt:MaximumMember 2021-04-01 2021-06-30 0001484565 srt:MaximumMember 2022-01-01 2022-06-30 0001484565 srt:MaximumMember 2021-01-01 2021-06-30 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanAndTwoThousandTwentyInducementEquityIncentivePlanMember 2021-12-31 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanAndTwoThousandTwentyInducementEquityIncentivePlanMember 2022-01-01 2022-06-30 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanAndTwoThousandTwentyInducementEquityIncentivePlanMember 2022-06-30 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanAndTwoThousandTwentyInducementEquityIncentivePlanMember 2021-01-01 2021-12-31 0001484565 us-gaap:EmployeeStockOptionMember 2022-06-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2021-04-01 2021-06-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2021-12-31 0001484565 us-gaap:RestrictedStockUnitsRSUMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2022-01-01 2022-06-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2022-06-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0001484565 us-gaap:EmployeeStockMember 2022-06-30 0001484565 us-gaap:EmployeeStockMember 2022-01-01 2022-06-30 0001484565 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-06-30 0001484565 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-06-30 0001484565 us-gaap:StockOptionMember 2022-01-01 2022-06-30 0001484565 us-gaap:StockOptionMember 2021-01-01 2021-06-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001484565 slno:UnderwriterMember 2021-01-01 2021-06-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2021-01-01 2021-06-30 0001484565 slno:TwoThousandTwentyTwoCommonWarrantsMember 2022-01-01 2022-06-30 0001484565 slno:TwoThousandTwentyTwoPreFundedWarrantsMember 2022-01-01 2022-06-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022 

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                  to                 

Commission File Number: 001-36593

 

SOLENO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

77-0523891

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

203 Redwood Shores Parkway, Suite 500

Redwood City, California

(Address of principal executive offices)

94065

(Zip Code)

(650) 213-8444

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

SLNO

NASDAQ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of August 4, 2022, there were 121,518,816 shares of the registrant’s Common Stock, par value $0.001 per share, outstanding.

 

 


 

SOLENO THERAPEUTICS, INC.

TABLE OF CONTENTS

 

 

Page

PART I—FINANCIAL INFORMATION

3

Item 1. Financial Statements

3

Condensed Consolidated Balance Sheets

3

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

4

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

5

Condensed Consolidated Statements of Cash Flows (unaudited)

6

Notes to Condensed Consolidated Financial Statements (unaudited)

7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

16

Item 3. Quantitative and Qualitative Disclosures About Market Risk

20

Item 4. Controls and Procedures

20

PART II—OTHER INFORMATION

21

Item 1. Legal Proceedings

21

Item 1A. Risk Factors

21

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

21

Item 3. Defaults Upon Senior Securities

21

Item 4. Mine Safety Disclosures

21

Item 5. Other Information

21

Item 6. Exhibits

21

EXHIBIT INDEX

22

SIGNATURES

23

 

 

 


 

 

PART I—FINANCIAL INFORMATION

Item 1.

Financial Statements

Soleno Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(In thousands except share and per share data)

 

 

 

June 30,

2022

 

 

December 31,

2021

 

Assets

 

(Unaudited)

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

24,065

 

 

$

21,304

 

Prepaid expenses and other current assets

 

 

824

 

 

 

1,118

 

Total current assets

 

 

24,889

 

 

 

22,422

 

Long-term assets

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

28

 

 

 

33

 

Operating lease right-of-use assets

 

 

279

 

 

 

421

 

Intangible assets, net

 

 

11,665

 

 

 

12,637

 

Other long-term assets

 

 

-

 

 

 

40

 

Total assets

 

$

36,861

 

 

$

35,553

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

2,406

 

 

$

3,254

 

Accrued compensation

 

 

932

 

 

 

728

 

Accrued clinical trial site costs

 

 

3,156

 

 

 

3,420

 

Operating lease liabilities

 

 

337

 

 

 

282

 

Other current liabilities

 

 

415

 

 

 

323

 

Total current liabilities

 

 

7,246

 

 

 

8,007

 

Long-term liabilities

 

 

 

 

 

 

 

 

2018 PIPE Warrant liability

 

 

2

 

 

 

31

 

Contingent liability for Essentialis purchase price

 

 

9,305

 

 

 

9,547

 

Long-term lease liabilities

 

 

 

 

 

175

 

Total liabilities

 

 

16,553

 

 

 

17,760

 

Commitments and contingencies (Note 6)

 

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

 

 

Common stock, $0.001 par value, 250,000,000 shares authorized,

   120,088,816 and 79,864,310 shares issued and outstanding at

   June 30, 2022 and December 31, 2021, respectively.

 

 

120

 

 

 

80

 

Additional paid-in-capital

 

 

245,993

 

 

 

231,068

 

Accumulated deficit

 

 

(225,804

)

 

 

(213,355

)

Accumulated other comprehensive loss

 

 

(1

)

 

 

 

Total stockholders’ equity

 

 

20,308

 

 

 

17,793

 

Total liabilities and stockholders’ equity

 

$

36,861

 

 

$

35,553

 

 

See accompanying notes to condensed consolidated financial statements

3


 

 

Soleno Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(In thousands except share and per share data)

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

$

3,696

 

 

$

5,587

 

 

$

7,684

 

 

$

12,751

 

General and administrative

 

2,467

 

 

 

2,464

 

 

 

5,110

 

 

 

5,443

 

Change in fair value of contingent consideration

 

616

 

 

 

3,034

 

 

 

(242

)

 

 

2,047

 

Total operating expenses

 

6,779

 

 

 

11,085

 

 

 

12,552

 

 

 

20,241

 

Operating loss

 

(6,779

)

 

 

(11,085

)

 

 

(12,552

)

 

 

(20,241

)

Other income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of warrants liabilities

 

2

 

 

 

56

 

 

 

29

 

 

 

257

 

Interest income

 

52

 

 

 

41

 

 

 

74

 

 

 

42

 

Total other income

 

54

 

 

 

97

 

 

 

103

 

 

 

299

 

Net loss

$

(6,725

)

 

$

(10,988

)

 

$

(12,449

)

 

$

(19,942

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

1

 

 

 

 

 

 

(1

)

 

 

 

Total comprehensive loss

$

(6,724

)

 

$

(10,988

)

 

$

(12,450

)

 

$

(19,942

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share, basic and diluted

$

(0.06

)

 

$

(0.14

)

 

$

(0.12

)

 

$

(0.25

)

Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share

 

120,088,816

 

 

 

79,747,506

 

 

 

100,165,432

 

 

 

79,721,290

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See accompanying notes to condensed consolidated financial statements

4


 

 Soleno Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

For the Three and Six Months Ended June 30, 2022 and 2021

(unaudited)

(In thousands except share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

 

Other

 

 

Total

 

 

 

Common Stock

 

 

Paid-In

 

 

Accumulated

 

 

Comprehensive

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Loss

 

 

Equity

 

Balances at January 1, 2022

 

 

79,864,310

 

 

$

80

 

 

$

231,068

 

 

$

(213,355

)

 

$

-

 

 

$

17,793

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

644

 

 

 

-

 

 

 

-

 

 

 

644

 

Issuance of restricted stock units under equity incentive plan

 

 

279,757

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

Tax withholding payments for net share-settled equity awards

 

 

(55,251

)

 

 

-

 

 

 

(16

)

 

 

-

 

 

 

-

 

 

 

(16

)

Sale of common stock and pre-funded warrants in public offering, net of costs of $1,034

 

 

40,000,000

 

 

 

40

 

 

 

13,726

 

 

 

-

 

 

 

-

 

 

 

13,766

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(5,724

)

 

 

-

 

 

 

(5,724

)

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2

)

 

 

(2

)

Balances at March 31, 2022

 

 

120,088,816

 

 

 

120

 

 

 

245,422

 

 

 

(219,079

)

 

 

(2

)

 

 

26,461

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

571

 

 

 

-

 

 

 

-

 

 

 

571

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(6,725

)

 

 

-

 

 

 

(6,725

)

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1

 

 

 

1

 

Balances at June 30, 2022

 

 

120,088,816

 

 

$

120

 

 

$

245,993

 

 

$

(225,804

)

 

$

(1

)

 

$

20,308

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

 

Other

 

 

Total

 

 

 

Common Stock

 

 

Paid-In

 

 

Accumulated

 

 

Comprehensive

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Loss

 

 

Equity

 

Balances at January 1, 2021

 

 

79,615,692

 

 

$

80

 

 

$

227,912

 

 

$

(182,445

)

 

$

-

 

 

$

45,547

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

1,095

 

 

 

-

 

 

 

-

 

 

 

1,095

 

Issuance of restricted stock units under equity incentive plan

 

 

167,060

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

Tax withholding payments for net share-settled equity awards

 

 

(59,072

)

 

 

-

 

 

 

(120

)

 

 

-

 

 

 

-

 

 

 

(120

)

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(8,954

)

 

 

-

 

 

 

(8,954

)

Balances at March 31, 2021

 

 

79,723,680

 

 

 

80

 

 

 

228,887

 

 

 

(191,399

)

 

 

-

 

 

 

37,568

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

857

 

 

 

-

 

 

 

-

 

 

 

857

 

Issuance of restricted stock units under equity incentive plan

 

 

35,545

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(10,988

)

 

 

-

 

 

 

(10,988

)

Balances at June 30, 2021

 

 

79,759,225

 

 

$

80

 

 

$

229,744

 

 

$

(202,387

)

 

$

-

 

 

$

27,437

 

 

See accompanying notes to condensed consolidated financial statements

5


 

Soleno Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(In thousands)

 

 

 

Six Months Ended June 30,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(12,449

)

 

$

(19,942

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

984

 

 

 

979

 

Non-cash lease expense

 

 

142

 

 

 

151

 

Stock-based compensation expense

 

 

1,215

 

 

 

1,952

 

Change in fair value of stock warrants

 

 

(29

)

 

 

(257

)

Change in fair value of contingent consideration

 

 

(242

)

 

 

2,047

 

Other non-cash reconciling items

 

 

(1

)

 

 

 

Change in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses, other current assets and other assets

 

 

334

 

 

 

83

 

Other Assets

 

 

-

 

 

 

(40

)

Accounts payable

 

 

(848

)

 

 

(153

)

Accrued compensation

 

 

204

 

 

 

(353

)

Accrued clinical trial site costs

 

 

(264

)

 

 

138

 

Operating lease liabilities

 

 

(120

)

 

 

(168

)

Other liabilities

 

 

92

 

 

 

62

 

Net cash used in operating activities

 

 

(10,982

)

 

 

(15,501

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(7

)

 

 

(4

)

Net cash used in investing activities

 

 

(7

)

 

 

(4

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from sale of common stock and pre-funded warrants, net of costs

 

 

13,766

 

 

 

 

Tax withholding payments for net share-settled equity awards

 

 

(16

)

 

 

(120

)

Principal paid on finance lease liabilities

 

 

 

 

 

(3

)

Net cash provided by (used in) financing activities

 

 

13,750

 

 

 

(123

)

Net increase (decrease) in cash and cash equivalents

 

 

2,761

 

 

 

(15,628

)

Cash and cash equivalents, beginning of period

 

 

21,304

 

 

 

49,224

 

Cash and cash equivalents, end of period

 

$

24,065

 

 

$

33,596

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of non-cash activities

 

 

 

 

 

 

 

 

Right-of-use assets obtained in exchange for operating lease obligations

 

$

-

 

 

$

581

 

Deferred financing costs included in accounts payable

 

$

-

 

 

$

12

 

 

See accompanying notes to condensed consolidated financial statements.

 


6


 

 

Soleno Therapeutics, Inc.

June 30, 2022

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 1. Overview

Soleno Therapeutics, Inc. (the Company or Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended Release tablets (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS). DCCR has received orphan designation for the treatment of PWS in the United States (U.S.) as well as in the European Union (E.U.).

The Company incorporated in the State of Delaware on August 25, 1999, and is located in Redwood City, California. It initially established its operations as Capnia, a diversified healthcare company that developed and commercialized innovative diagnostics, devices and therapeutics addressing unmet medical needs.  During 2017, the Company merged with Essentialis, Inc (Essentialis) and subsequently received stockholder approval to amend its Amended and Restated Certificate of Incorporation to change its name from “Capnia, Inc.” to “Soleno Therapeutics, Inc.” Essentialis was a privately held clinical-stage company focused on the development of breakthrough medicines for the treatment of rare diseases where there is increased mortality and risk of cardiovascular and endocrine complications. After the merger, the Company’s primary focus has been the development and commercialization of novel therapeutics for the treatment of rare diseases and the Company divested all prior business efforts.

Note 2. Going Concern and Management’s Plans

The Company had a net loss of $12.4 million during the six months ended June 30, 2022 and has an accumulated deficit of $225.8 million at June 30, 2022 resulting from having incurred losses since its inception. The Company had $24.1 million of cash and cash equivalents on hand at June 30, 2022 and used $11.0 million of cash in its operating activities during the six months ended June 30, 2022. The Company has financed its operations principally through issuances of equity securities. In March 2022, the Company completed a public offering of 40,000,000 shares of its common stock and, for certain investors, in lieu of common stock, pre-funded warrants to purchase 20,000,000 shares of common stock at an exercise price of $0.01 per share, and raised $13.8 million in net proceeds after deducting the underwriting discount and other estimated offering costs. Each share of common stock or pre-funded warrant was sold together with one immediately exercisable common warrant to purchase one share of common stock.

The accompanying condensed consolidated financial statements have been prepared under the assumption the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

The Company expects to continue incurring losses for the foreseeable future and will be required to raise additional capital to complete its clinical trials, pursue product development initiatives, obtain regulatory approval and penetrate markets for the sale of its products. Management believes that the Company will continue to have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means, but the Company’s access to such capital resources is uncertain and is not assured. If the Company is unable to secure additional capital, it may be required to curtail its clinical trials and development of new products and take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s efforts to complete its clinical trials and commercialize its products, which are critical to the realization of its business plan and the future operations of the Company.

Management believes that the Company does not have sufficient capital resources to sustain operations through at least the next twelve months from the date of this filing. Additionally, in view of the Company’s expectation to incur significant losses for the foreseeable future it will be required to raise additional capital resources in order to fund its operations, although the availability of, and the Company’s access to such resources is not assured. Accordingly, management believes that there is substantial doubt regarding the Company’s ability to continue operating as a going concern through at least the next twelve months from the date of this filing.

7


 

Note 3. Basis of Presentation and Summary of Significant Accounting Policies

Significant Accounting Policies

There have been no material changes to the significant accounting policies during the six months ended June 30, 2022 as compared to the significant accounting policies described in Note 3 of the “Notes to Consolidated Financial Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three and six months ended June 30, 2022, are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2022. For further information, refer to the financial statements and footnotes included in the Company’s annual financial statements for the fiscal year ended December 31, 2021, which are included in the Company’s annual report on Form 10-K filed with the SEC on March 31, 2022.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, accrued costs for services rendered in connection with third-party contractor clinical trial activities, and the valuation of contingent liabilities for the purchase price of assets obtained through acquisition.

Recent Accounting Standards

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date.

During the three and six months ended June 30, 2022, there have been no recently adopted accounting standards and no new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s condensed consolidated interim financial statements.

Note 4. Fair Value of Financial Instruments

The carrying value of the Company’s cash, cash equivalents and accounts payable, approximate fair value due to the short-term nature of these items.

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

 

Level I Unadjusted quoted prices in active markets for identical assets or liabilities;

 

Level II Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

 

Level III Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

8


 

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands).

 

 

 

Fair Value Measurements at June 30, 2022

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2018 PIPE warrant liability

 

$

2

 

 

$

 

 

$

 

 

$

2

 

Essentialis purchase price contingency liability

 

 

9,305

 

 

 

 

 

 

 

 

 

9,305

 

Total common stock warrant and contingent

   consideration liability

 

$

9,307

 

 

$

 

 

$

 

 

$

9,307

 

 

 

 

Fair Value Measurements at December 31, 2021

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2018 PIPE warrant liability

 

$

31

 

 

$

 

 

$

 

 

$

31

 

Essentialis purchase price contingency liability

 

 

9,547

 

 

 

 

 

 

 

 

 

9,547

 

Total common stock warrant and contingent

   consideration liability

 

$

9,578

 

 

$

 

 

$

 

 

$

9,578

 

 

The Company’s estimated fair value of the 2018 PIPE Warrants was calculated using a Black-Scholes pricing model. The Black-Scholes pricing model requires the input of highly subjective assumptions including the expected stock price volatility, the expected term, the expected dividend yield and the risk-free interest rate.

Based on the terms of the Company’s completed merger with Essentialis on March 7, 2017, the Company was obligated to make cash earnout payments of up to a maximum of $30.0 million to the former Essentialis stockholders. On December 28, 2021, in connection with the dissolution of two of the former Essentialis stockholders, the two former stockholders entered into an agreement with the Company which assigned the right, title and interest to all their future earnout payments to the Company. As a result of the assignment, as of December 31, 2021, and going forward, the maximum cash earnout payments are $21.2 million. The fair value of the Essentialis purchase price contingent liability is estimated using scenario-based methods based upon the Company’s analysis of the likelihood of obtaining specified approvals from the U.S. Food and Drug Administration (FDA) as well as the likelihood and anticipated timing of reaching cumulative revenue milestones. The Level 3 estimates are based, in part, on subjective assumptions. In determining the likelihood of obtaining FDA approval, the analysis relied on published research relating to clinical development success rates. Based on management’s assessment, a 72% probability of achieving each milestone was determined to be reasonable as of each of June 30, 2022 and December 31, 2021. During the periods presented, the Company has not changed the manner in which it values its Essentialis purchase price contingent liability.

The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers between levels within the hierarchy during the periods presented.

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2022 and 2021 (dollars in thousands).

 

 

 

2018 PIPE Warrants

 

 

Purchase Price

 

 

 

Number of

Warrants

 

 

Liability

 

 

Contingent

Liability

 

Balance at January 1, 2022

 

 

513,617

 

 

$

31

 

 

$

9,547

 

Change in value of 2018 PIPE Warrants

 

 

 

 

 

(29

)

 

 

 

Change in value of contingent liability

 

 

 

 

 

 

 

 

(242

)

Balance at June 30, 2022

 

 

513,617

 

 

$

2

 

 

$

9,305